Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Keros Therapeutics Inc shares valued at $11,002,500 were sold by GORDON CARL L on Aug 13 ’24. At $44.01 per share, GORDON CARL L sold 250,000 shares. The insider’s holdings dropped to 119,522 shares worth approximately $1.9 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, ORBIMED ADVISORS LLC sold 250,000 shares, netting a total of over 11,002,500 in proceeds. Following the sale of shares at $44.01 each, the insider now holds 119,522 shares.
Before that, OrbiMed Genesis Master Fund, L had added 29,400 shares to its account. In a trade valued at $1,318,296, the Shareholder bought Keros Therapeutics Inc shares for $44.84 each.
As published in a research note from Oppenheimer on December 16, 2024, Keros Therapeutics Inc [KROS] has been retained to an Outperform and the price target has been revised to $63. Analysts at Guggenheim downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in mid December. As of December 13, 2024, H.C. Wainwright has reiterated its “Buy” rating for KROS. Earlier on December 12, 2024, William Blair downgraded its rating. Their new recommendation was “a Mkt perform” for KROS stock which previously was a “an Outperform”.
Analyzing KROS Stock Performance
During the last five days, there has been a drop of approximately -4.73%. Over the course of the year, Keros Therapeutics Inc shares have jumped approximately 0.57%. Shares of the company reached a 52-week high of $16.70 on 01/02/25 and a 52-week low of $15.82 on 01/02/25. A 50-day SMA is recorded $48.78, while a 200-day SMA reached $52.08. Nevertheless, trading volume fell to 0.52 million shares from 1.14 million shares the previous day.
Support And Resistance Levels for Keros Therapeutics Inc (KROS)
According to the 24-hour chart, there is a support level at 15.59, which, if violated, would cause prices to drop to 15.27. In the upper region, resistance lies at 16.47. The next price resistance is at 17.03. RSI (Relative Strength Index) is 22.66 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.36, which suggests the price will decrease in the coming days. Percent R is at 89.69%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
